Background: The rapid evolution of palliative therapeutic choices in the last few years for patients with advanced castration-resistant prostate cancer (CRPC) has resulted in a dilemma currently troubling a few other epithelial malignancies: which systemic agent to choose and at what time? In addition, which specialty specifically directs the delivery of such care-Urology or Medical Oncology-has not been clearly established. Approach: Recognizing the lack of consensus, we propose a framework for Urology and Medical Oncology interactions that is founded on models that have succeeded in the past. Conclusion: This approach aims to focus the care on the patient with CRPC rather than on his physicians and promises to improve patient outcomes in this disease state.
|Original language||English (US)|
|Number of pages||3|
|Journal||Urologic Oncology: Seminars and Original Investigations|
|State||Published - 2014|
- Castration-resistant prostate cancer
- Medical urology
ASJC Scopus subject areas